| 前收盘价格 | 50.10 |
| 成交量 | 1,642,136 |
| 预期市盈率 (P/E Forward) | 15.45 |
| 价格/销量 (P/S) | 4.91 |
| 股市价格/股市净资产 (P/B) | 2.96 |
| 52周波幅 | |
| 股息率 (DY TTM) | 0.64% |
| 营业毛利率 | 4.68% |
| 营业利益率 (TTM) | 25.89% |
| 稀释每股收益 (EPS TTM) | 0.430 |
| 季度收入增长率 (YOY) | 5.40% |
| 季度盈利增长率 (YOY) | 12.50% |
| 总债务/股东权益 (D/E MRQ) | 41.36% |
| 流动比率 (MRQ) | 3.37 |
| 营业现金流 (OCF TTM) | 680.21 M |
| 杠杆自由现金流 (LFCF TTM) | 622.84 M |
| 资产报酬率 (ROA TTM) | 5.75% |
| 股东权益报酬率 (ROE TTM) | 2.67% |
AIStockmoo 评分
| 价值 30% | 0.5 |
| 接近其一贯估值。因盈利不稳,计入较少。 参考 | |
| 资本回报低于资本成本。 参考 | |
| 负债低。盈利能力弱。短期流动性充足。现金流为正。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | 2.2 |
| 过去一年没有明确趋势。股价接近52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价接近均线。上涨日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 4.8 |
| 机构在最新13F申报中净+6.34%的股份:218家增持,153家减持(截至30 Sep 2026的季度)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况有利。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利有升有降。盈利不稳。 参考 | |
| 高于中期趋势线。 参考 | |
| 股价高于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向上。短期动能减弱。 参考 | |
| 股价接近阻力位。支撑与阻力水平趋升。 参考 | |
| 最终评分 | 2.27 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Qiagen N.V. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| QGEN | - | 0.64% | - | 2.96 | 2.3 |
| RVTY | 17 B | 0.18% | 67.67 | 2.34 | 0.9 |
| CRL | 16 B | - | 356.45 | 4.94 | 0.7 |
| TMO | 248 B | 0.27% | 35.31 | 4.69 | 0.7 |
| DHR | 155 B | 0.67% | 36.48 | 3.00 | 0.4 |
| WAT | 87 B | - | 184.29 | 5.99 | 1.2 |
|
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%). |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 1.61% |
| 机构持股比例 | 86.26% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 76.28%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 218 | 31,874,519 |
| 减持 | 153 | 18,912,886 |
| 新建仓 | 67 | 5,570,055 |
| 清仓 | 52 | 5,474,496 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
0 正面
1 负面
3 中性
| 日期 | 类型 | 细节 |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Interpreting Qiagen (QGEN) International Revenue Trends
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
| 11 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
Qiagen (NYSE:QGEN) received shareholder approval at an Extraordinary General Meeting for Jonathan M. Pratt to become CEO and Managing Director. Jonathan M. Pratt is set to succeed Thierry Bernard in the top leadership role following the Extraordinary General Meeting vote. The board decision… |
| 06 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands
Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3%… |
| 06 Nov 2026 | Yahoo Finance |
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
VENLO, Netherlands, November 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of… |
技术形态 中期
趋势排列
斜率
入场位置
成交量
上升趋势:股价位于均线之上,均线向上。股价接近均线。上涨日成交量较大。
最近支撑: 47.11 – 47.45 · 中等
最近阻力: 49.90 – 50.24 · 中等
AI 技术分析
投资组合